ASH Conference Coverage
(Reuters) Dec 9, 2019 - Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.
The lowest dose of the therapy, bb21217, had a median duration of response of...
(ASH) Dec 10, 2019 - The immunotherapy drug blinatumomab significantly improved survival in children with relapsed B-acute lymphoblastic leukemia (B-ALL) compared with standard chemotherapy in a study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando.
Researchers say the...